DE60223556D1 - Medizinische verwendung von stammzellen, die vegfr-1 exprimieren - Google Patents

Medizinische verwendung von stammzellen, die vegfr-1 exprimieren

Info

Publication number
DE60223556D1
DE60223556D1 DE60223556T DE60223556T DE60223556D1 DE 60223556 D1 DE60223556 D1 DE 60223556D1 DE 60223556 T DE60223556 T DE 60223556T DE 60223556 T DE60223556 T DE 60223556T DE 60223556 D1 DE60223556 D1 DE 60223556D1
Authority
DE
Germany
Prior art keywords
stem cells
cells expressing
vegfr
directed
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60223556T
Other languages
English (en)
Other versions
DE60223556T2 (de
Inventor
Shahin Rafii
Larry Witte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
ImClone LLC
Original Assignee
Cornell Research Foundation Inc
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc, ImClone Systems Inc filed Critical Cornell Research Foundation Inc
Application granted granted Critical
Publication of DE60223556D1 publication Critical patent/DE60223556D1/de
Publication of DE60223556T2 publication Critical patent/DE60223556T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
DE60223556T 2001-08-10 2002-08-12 Medizinische verwendung von stammzellen, die vegfr-1 exprimieren Expired - Fee Related DE60223556T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31170501P 2001-08-10 2001-08-10
US311705P 2001-08-10
PCT/US2002/025657 WO2003014326A2 (en) 2001-08-10 2002-08-12 Isolation and mobilization of stem cells expressing vegfr-1

Publications (2)

Publication Number Publication Date
DE60223556D1 true DE60223556D1 (de) 2007-12-27
DE60223556T2 DE60223556T2 (de) 2008-09-18

Family

ID=23208088

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223556T Expired - Fee Related DE60223556T2 (de) 2001-08-10 2002-08-12 Medizinische verwendung von stammzellen, die vegfr-1 exprimieren

Country Status (9)

Country Link
US (1) US20050026220A1 (de)
EP (1) EP1423012B1 (de)
JP (1) JP2005526482A (de)
AT (1) ATE378056T1 (de)
AU (1) AU2002355580A1 (de)
CA (1) CA2454251A1 (de)
DE (1) DE60223556T2 (de)
ES (1) ES2299590T3 (de)
WO (1) WO2003014326A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288521B2 (en) * 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
EP1458853B1 (de) 2002-05-16 2009-11-25 Absorber AB Verfahren für donorspezifisches crossmatching
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US20060104963A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
US20060104962A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
JP2007536936A (ja) * 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 幹細胞集団および使用方法
AU2005285246B2 (en) * 2004-09-03 2011-07-21 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
WO2007021210A1 (fr) * 2005-08-15 2007-02-22 Krasnozhenyuk Alexei Dmitrievi Methode de traitement de maladies causees par une pathologie vasculaire
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
GB0818725D0 (en) 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US5543503A (en) * 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
DE69332948T2 (de) * 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
JP3658471B2 (ja) * 1996-09-30 2005-06-08 株式会社日立製作所 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
ATE331806T1 (de) * 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
AU5250200A (en) * 1999-06-17 2001-01-09 Kyowa Hakko Kogyo Co. Ltd. Diagnostics and remedies for diseases with participation of macrocytes/macrophages
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
EP1272208B1 (de) * 2000-04-12 2011-10-05 VIB vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
EP1299419A2 (de) * 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispezifische immunglobulinartige antigenbindende proteine und verfahren zur deren herstellung
AU2002316305A1 (en) * 2001-06-20 2003-01-08 Vlaams Interuniversitair Institut Voor Biotechnologie Method of treating atherosclerosis and other inflammatory diseases
JP2005518336A (ja) * 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
US20040241160A1 (en) * 2001-07-13 2004-12-02 Yan Wu Vegfr-1 antibodies to treat breast cancer
US20070142401A1 (en) * 2003-10-27 2007-06-21 Novartis Ag Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors

Also Published As

Publication number Publication date
AU2002355580A1 (en) 2003-02-24
ES2299590T3 (es) 2008-06-01
DE60223556T2 (de) 2008-09-18
EP1423012A2 (de) 2004-06-02
WO2003014326A2 (en) 2003-02-20
ATE378056T1 (de) 2007-11-15
WO2003014326A3 (en) 2003-04-10
EP1423012A4 (de) 2005-01-05
EP1423012B1 (de) 2007-11-14
JP2005526482A (ja) 2005-09-08
CA2454251A1 (en) 2003-02-20
US20050026220A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
ATE378056T1 (de) Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
DE69738640D1 (de) Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
NO20052928L (no) Nye kjemiske forbindelser
ATE473275T1 (de) Menschliche aminoacyl-trna synthetase polypeptide zur regulation der angiogenese
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DK1129190T3 (da) Human TSLP DNA og polypeptider
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
ATE323692T1 (de) Piperidinylsubstituierte pyridylalkan-, -alken- und -alkincarbonsäuren als cytostatika und immunsuppressiva
NO20051967L (no) 3,4-disubstituerte pyroler og deres anvendelse ved behandling av inflammatoriske sykdommer.
DE69933696D1 (de) Cytokinrezeptor-kette
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
ATE255584T1 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
Gasmi et al. Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom: ICPP is angiogenic via vascular endothelial growth factor receptor signaling
DK0769024T3 (da) Höjaffinitetsmelatoninreceptor og anvendelser deraf
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
ATE557092T1 (de) Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
DE602004001509D1 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
ES2064375T3 (es) Factor del estres humano por calor.
ATE393825T1 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung
DE60238333D1 (de) Auf antibiotikum basierendes genregulationssystem

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee